Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU

Core Insights - Novavax has officially transferred the marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi within the European Union [3] - As a result of this transfer, Novavax received a milestone payment of $25 million [3] - This strategic move allows Sanofi to take over the marketing responsibilities for the vaccine [3]